Bladder Cancer

Notice of U.S. patent allowance for superficial bladder cancer drug received

Published in Medical Letter on the CDC and FDA, February 20th, 2005

Spectrum Pharmaceuticals, Inc. (SPPI) announced that it has received from the U.S. Patent and Trademark Office (PTO) a Notice of Allowance for its patent application for EOquin entitled "Medical Compositions for Intravesical Treatment of Bladder Cancer."

This patent, when issued, protects EOquin for use in the treatment of superficial bladder cancer and will not expire until November 2022.

Spectrum Pharmaceuticals announced the completion of enrollment in EOquin multi-center phase 2 trial for refractory superficial bladder cancer on January 6, 2005. The company plans to present phase 2 data on EOquin at the European Association of Urologists...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry